
Clinical trials of the world’s first “tooth regrowth medicine” is set to begin this September at Kyoto University Hospital in Japan.
The drug has already successfully regrown teeth in ferrets and mice which share similar USAG-1 properties to humans with no major side effects.
The first phase of the trial will run until August 2025 with the drug being administered intravenously to healthy males aged between 30 and 64. Subjects must be missing at least one back tooth to confirm there will be no problems when a tooth begins to grow.
The following stage will involve patients with congenital tooth deficiency from birth.
The drug deactivates a protein called USAG-1, which inhibits the growth of teeth. Researchers believe that it may be possible to grow teeth not only in people with congenital conditions, but also in those who have lost teeth due to cavities or injuries.
If trials are successful, the researchers hope to commence sale of the medicine in 2030.
Source: mainichi.jp